Penn Undergraduate Law Journal
  • Home
  • About
    • Mission
    • Masthead
    • Faculty Advisory Board
    • Partner Journals
    • Sponsors
  • Submissions
  • Full Issues
  • The Roundtable
    • Pre-Law Corner
  • Events
  • Contact
    • Contact
    • Apply
    • FAQs
  • Home
  • About
    • Mission
    • Masthead
    • Faculty Advisory Board
    • Partner Journals
    • Sponsors
  • Submissions
  • Full Issues
  • The Roundtable
    • Pre-Law Corner
  • Events
  • Contact
    • Contact
    • Apply
    • FAQs

The Roundtable


Welcome to the Roundtable, a forum for incisive commentary and analysis
on cases and developments in law and the legal system.


The Race Against COVID-19: Vaccine Development

5/10/2020

2 Comments

 
Picture
By Rachel Gu
Rachel Gu is a sophomore in the School of Engineering and Applied Sciences at the University of Pennsylvania studying Bioengineering.
​On March 11th, the World Health Organization (WHO) declared COVID-19 a global pandemic. Since then, the number of confirmed cases has risen tenfold from 118,000 cases to over 1.8 million cases worldwide [1]. Of these, the U.S. houses over half a million cases with over 20,000 deaths and counting [2]. However, these numbers only showcase the beginning. Experts predict deaths will increase over threefold to about 70,000 by August when the projected infection curve finally begins to flatten [3]. Not to mention, experts predict a second wave of mass infection as society gradually returns to normalcy [4]. As a result, vaccine development is paramount in combating this global pandemic. However, due to the pressure of rising fatalities and plummeting economies, typical rules and regulations are being bypassed by researchers and regulators. In this race to develop vaccines, safety, liability and patent contention must be considered. 
So far, the U.S. Food and Drug Administration has deployed Emergency Use Authorizations (EUA) to allow the rapid development of drugs. Under section 564 of the Federal Food, Drug, and Cosmetic Act, the FDA may allow unapproved medical products to be used in an emergency that has significant potential to affect national security when there are no existing adequate, approved alternatives [5]. In fact, a test developed by Swiss pharma giant Roche was EUA-approved in just one day, and Thermo Fisher’s new diagnostic test was also cleared due to the large deficit in available testing kits both nationally and internationally. Even more radical, the FDA has allowed state-level authorities in New York to coordinate COVID-19 patient testing, eliminating federal oversight entirely [6].

Given these accelerated deviations from the ordinary course of action, safety and liability issues inevitably arise. However, the Department of Health and Human Services (HHS) declared under the Public Readiness and Emergency Preparedness (PREP) Act that manufacturers and distributors are given liability immunity from medical countermeasures against COVID-19 effective February 4th, 2020, except for claims involving “willful misconduct.” Any diagnostic tests, treatment, or vaccines that are FDA-approved––even under EUA––qualify under this act [7]. However, certain individuals who are seriously injured or die as a direct result of a covered medical countermeasure may be eligible to obtain benefits through the government’s Countermeasures Injury Compensation Program (CICP). This program is a last resort payer who only covers expenses that third-party payers, such as health insurance or Workers’ Compensation programs, do not have an obligation to pay [8].

With no established cure on the market, panicked citizens can easily fall for treatment and testing dupes. On March 22nd, the first federal action against COVID-19 fraud was announced. The owners of fraudulent website coronavriusmedicalkit.com claimed to offer consumers access to WHO vaccine kits in exchange for a low shipment charge, despite there being no legitimate COVID-19 vaccines. In response, U.S. District Judge Robert Pitman issued a temporary restraining order on this website while the FBI continues to investigate the allegations. Judge Pitman hopes this case inspires responsible web domain registrars to quickly shut down future scamming websites exploiting a national emergency for personal gain [9].

Along with the race to develop an effective vaccine against COVID-19, a new source of contention emerges: the ownership of the vaccine patent rights. A patent gives the inventor an exclusivity period during which they may control who can use or sell their product. Although there is currently no COVID-19 vaccine, pharmaceutical companies in China, the U.S, and Europe report they are all nearing successful treatment production. While Europe has reassured that a vaccine first developed and patented in Europe will be globally licensed to ensure access to all populations, not every leading nation has ensured the same course of action. Given current tensions between the U.S. and China, critics fear that vaccine patent ownership may be used as a political bargaining chip.

Micro examples of this behavior have already occured. U.S. pharmaceutical laboratory Gilead owns the patent rights to antiviral medication Remesdivir. While this treatment was first developed for Ebola during the outbreak in 2014, it is currently the only known antiviral believed to be effective at treating coronavirus strains such as COVID-19. To test the efficacy of this medication, Gilead donated Remesdivir samples to hospitals in China in response to China’s massive outbreak. After receiving these treatment samples, the Wuhan Institute of Virology filed a competing “method of use” patent for a combination treatment of Remesdivir and chloroquine––a common malaria antiviral. Wuhan Institute issued a statement along with its patent application, declaring that the patent application was filed in the “nation’s interest” and that they would not enforce the patent rights if foreign pharmaceutical companies agreed to collaborate with China in addressing COVID-19 [10].

Wuhan Institute ostensibly filed for a Remesdevir patent purely as a defensive measure to secure access to a promising treatment in China, indicating a clear mistrust between the two nations. However, this action, along with poor historical evidence of China enforcing American patent rights, could signal to other foreign pharmaceuticals, such as Johnson & Johnson, BioNTech, and CureVac, not to test their treatments in China in fear that their intellectual property rights will not be upheld.

Despite the declaration of a global pandemic with millions of lives at stake, the COVID-19 vaccine could provide leverage to either nation in the escalating trade war between the U.S. and China. Only time will tell if political conflicts will threaten public access to essential medicines: a battle between the prioritization of human lives or political power.

​​​​​​The opinions and views expressed in this publication are the opinions of the designated authors and do not reflect the opinions or views of the Penn Undergraduate Law Journal, our staff, or our clients.
References
[1] Ducharme, J. (2020, March 11). The WHO Just Declared Coronavirus COVID-19 a Pandemic. Time. Retrieved from https://time.com/5791661/who-coronavirus-pandemic-declaration/
[2] Coronavirus Disease 2019 (COVID-19) Situation Report-85. (2020, April 14th). World Health Organization. Retrieved from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200414-sitrep-85-covid-19.pdf?sfvrsn=7b8629bb_4
[3] IHME: COVID-19 Projections. (2020, April 13). Institute for Health Metrics and Evaluation. Retrieved from https://covid19.healthdata.org/united-states-of-america
[4] Xu, S. & Li, Y. (2020, April 8). Beware of the Second Wave of COVID-19. The Lancet. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30845-X/fulltext
[5] Emergency Use Authorization. (2020, April 16). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
[6] Wentworth, S. (2020, March 25). The legal and regulatory context of R&D during COVID-19. The Pharma Letter. Retrieved from https://www.thepharmaletter.com/article/the-legal-and-regulatory-context-of-r-d-during-covid-19
[7] DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary. (2020, February 4). U.S. Department of Health & Human Services. Retrieved from https://www.phe.gov/Preparedness/legal/prepact/Pages/COVID19.aspx
[8] Countermeasures Injury Compensation Program. (2017, October). Health Resources & Services Administration. Retrieved from https://www.hrsa.gov/sites/default/files/hrsa/cicp/cicpfactsheet.pdf
[9] Justice Department Files Its First Enforcement Action Against COVID-19 Fraud. (2020, March 24). United States Department of Justice. Retrieved from https://www.justice.gov/opa/pr/justice-department-files-its-first-enforcement-action-against-covid-19-fraud
[10] Harasimowicz, R. (2020, March 24). The Global Patent Race for a COVID-19 Vaccine. The National Law Review. Retrieved from https://www.natlawreview.com/article/global-patent-race-covid-19-vaccine

Photo by National Cancer Institute on Unsplash
2 Comments
Linda
5/11/2020 04:21:30 pm

Nice writing

Reply
Applya Loans link
5/14/2020 05:47:51 am

Vaccine should be develop soon i hope all the countries are researching for it
Hope for the best

Reply

Your comment will be posted after it is approved.


Leave a Reply.


    Categories

    All
    Aaron Tsui
    Akshita Tiwary
    Alana Bess
    Alana Mattei
    Albert Manfredi
    Alexander Saeedy
    Alexandra Aaron
    Alexandra Kanan
    Alexandra Kerrigan
    Alice Giannini
    Alicia Augustin
    Alicia Kysar
    Ally Kalishman
    Ally Margolis
    Alya Abbassian
    Amanda Damayanti
    Anika Prakash
    Anna Schwartz
    Arshiya Pant
    Ashley Kim
    Astha Pandey
    Audrey Pan
    Benjamin Ng'aru
    Brónach Rafferty
    Bryce Klehm
    Cary Holley
    Catherine Tang
    Christina Gunzenhauser
    Christine Mitchell
    Christopher Brown
    Clarissa Alvarez
    Cole Borlee
    Connor Gallagher
    Dan Spinelli
    Dan Zhang
    David Katz
    Davis Berlind
    Derek Willie
    Dhilan Lavu
    Edgar Palomino
    Edna Simbi
    Ella Jewell
    Ella Sohn
    Emma Davies
    Esther Lee
    Evelyn Bond
    Filzah Belal
    Frank Geng
    Gabrielle Cohen
    Gabriel Maliha
    Georgia Ray
    Graham Reynolds
    Habib Olapade
    Hailie Goldsmith
    Haley Son
    Hannah Steinberg
    Harshit Rai
    Hennessis Umacta
    Henry Lininger
    Hetal Doshi
    Ingrid Holmquist
    Iris Zhang
    Irtaza Ali
    Isabela Baghdady
    Ishita Chakrabarty
    Jack Burgess
    Jessica "Lulu" Lipman
    Joe Anderson
    Jonathan Lahdo
    Jonathan Stahl
    Joseph Squillaro
    Justin Yang
    Kaitlyn Rentala
    Kanishka Bhukya
    Katie Kaufman
    Kelly Liang
    Keshav Sharma
    Ketaki Gujar
    Khlood Awan
    Lauren Pak
    Lavi Ben Dor
    Libby Rozbruch
    Lindsey Li
    Luis Bravo
    Lyan Casamalhuapa
    Lyndsey Reeve
    Madeline Decker
    Maja Cvjetanovic
    Maliha Farrooz
    Marco DiLeonardo
    Margaret Lu
    Matthew Caulfield
    Michael Keshmiri
    Michael Merolla
    Mina Nur Basmaci
    Muskan Mumtaz
    Natalie Peelish
    Natasha Darlington
    Natasha Kang
    Nathan Liu
    Nayeon Kim
    Nicholas Parsons
    Nicholas Williams
    Nicole Greenstein
    Nicole Patel
    Nihal Sahu
    Omar Khoury
    Owen Voutsinas Klose
    Owen Voutsinas-Klose
    Paula Vekker
    Pheby Liu
    Pragat Patel
    Rachel Bina
    Rachel Gu
    Rachel Pomerantz
    Rebecca Heilweil
    Regina Salmons
    Sajan Srivastava
    Samantha Graines
    Sandeep Suresh
    Sanjay Dureseti
    Sarah Simon
    Saranya Das Sharma
    Saranya Sharma
    Sasha Bryski
    Saxon Bryant
    Sean Foley
    Sebastian Bates
    Serena Camici
    Shahana Banerjee
    Shannon Alvino
    Shiven Sharma
    Siddarth Sethi
    Sneha Parthasarathy
    Sneha Sharma
    Sophie Lovering
    Steven Jacobson
    Suaida Firoze
    Suprateek Neogi
    Takane Shoji
    Tanner Bowen
    Taryn MacKinney
    Thomas Cribbins
    Todd Costa
    Tyler Larkworthy
    Tyler Ringhofer
    Vatsal Patel
    Vikram Balasubramanian
    Vishwajeet Deshmukh
    Wajeeha Ahmad
    Yeonhwa Lee

    Archives

    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    September 2024
    May 2024
    April 2024
    January 2024
    December 2023
    November 2023
    May 2023
    March 2023
    January 2023
    December 2022
    November 2022
    September 2022
    June 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    April 2019
    March 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    December 2017
    November 2017
    October 2017
    August 2017
    July 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    April 2016
    March 2016
    February 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    November 2014
    October 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    December 2013
    November 2013
    October 2013
    September 2013

Powered by Create your own unique website with customizable templates.